PIN13 ECONOMIC EVALUATION OF VORICONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN GERMANY  by Jansen, J et al.
762 Abstracts
otitis media. CONCLUSIONS: Universal infant vaccination with
PCV-7 has intermediate cost-effectiveness, therefore, regional
policies are warranted, according to local epidemiology of the
disease.
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OBJECTIVES: To assess the costs and cost-effectiveness of
voriconazole in comparison to conventional amphotericin B for
the treatment of invasive aspergillosis in Germany. METHODS:
The cost-effectiveness of voriconazole in comparison to conven-
tional amphotericin B was evaluated with a life-time Markov
model, focusing on the long-term survival of patients treated for
invasive aspergillosis. Long term survival was extrapolated from
survival after 12 weeks of treatment, obtained from a large ran-
domized aspergillosis study (Herbrecht et al. NEJM, 2002).
Information on medical resource consumption, treatment path-
ways and switch rates were obtained from both this randomized
study and an expert committee. Probabilistic analysis was used
to evaluate the cost-effectiveness of voriconazole compared to
amphotericin B, and was expressed by the incremental costs per
life weeks gained. The evaluation was performed from an insur-
ance perspective (both inpatient and outpatient costs) and hos-
pital perspective (direct costs, inpatient). RESULTS: The mean
survival of patients treated with voriconazole was 174.4 life
weeks (95%CI 159.4; 191.3), compared to 119.4 life weeks
(95%CI 106.4; 132.3) for amphotericin B. With voriconazole,
the total mean costs for treating invasive aspergillosis per patient
were 31,765€ (95%CI 24,094€; 39,383€) compared to 28,569€
for amphotericin B (95%CI €22,674; €36,860) from the insur-
ance perspective. Total inpatient costs were approximately 85%
of the total mean costs of treating aspergillosis infection. The
corresponding incremental cost-effectiveness ratio was 18€ per
life week gained, resulting in a >99% probability of being cost-
effective for a willingness-to-pay threshold of 20,000€ per life
year gained. CONCLUSIONS: In the treatment of invasive
aspergillosis, voriconazole is cost-effective in comparison to
amphotericin B. Inpatient costs had been represented within the
current German reimbursement system (per diem charges), but
are higher than those currently reimbursed within the newly
introduced German DRG system.
PIN14
CALCULATING THE COST OF WOUND CARE IN A
COMMUNITY SETTING IN THE UK: AN EXAMPLE USING
MODERN WOUND MANAGEMENT DRESSINGS
Orme ME1, Daniels S2
1Heron Evidence Development, Letchworth Garden City, UK;
2ConvaTec UK Ltd, Ickenham, Uxbridge, UK
OBJECTIVES: A review of debriding agents found that wound
care costs are very sensitive to the frequency of dressings change
particularly home wound care requiring a visit by a nurse.
(NICE, 2001) Modern wound dressings increase the time
between dressing changes freeing up nursing resources. The
objective of this paper is to show the relationship between fre-
quency of change, nursing resources and wound care costs.
METHODS: A simple model has been developed to help NHS
professionals in the UK estimate the wound care costs in their
local practice. The cost calculation is based upon the use of
wound dressings and nurse resources. Resource use depends
upon type of wound and treatment setting (hospital or commu-
nity), and frequency of change depends upon type of dressing.
Unit costs for dressings are from the Drug Tariff (May 2004) or
NHS Stores Catalogue (October 2003) and the nursing costs
from PSSRU (Netten 2003) depending upon treatment setting.
In this analysis, we considered a sloughy pressure ulcer with
medium exudate treated in a community setting by a district
nurse. Assuming the wound is managed using modern wound
dressings, typical treatment could be a ﬁbrous hydrocolloid
wound contact dressing and a sacral semi-permeable hydrocol-
loid secondary dressing. The frequency of change for this strat-
egy is once per week. RESULTS: The weekly cost of this strategy
would be £30.10 including dressing materials (£7.84), nurse time
to change dressings (£15.33) and time spent travelling to/from
patient (£6.93). Hence dressing resources account for just 26%
of the total cost. CONCLUSIONS: The main cost drivers in
wound care are the frequency of dressing change and the asso-
ciated nursing time required to change the dressing. Choice of
dressing should be based on an assessment of the frequency 
with which it can be changed and not just the unit cost of the
dressing.
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OBJECTIVES: Rotavirus (RV) infections are probably the most
important cause of severe acute gastroenteritis (AGE) in infants
and children up to 4 years of age. Evidence on the overall burden
of RV-AGE in Germany is limited, especially due to under-report-
ing. The objective is to estimate the burden of disease and cost-
of-illness of RV-AGE in Germany. METHODS: Data on
incidence of community-acquired and nosocomial infections as
well as related health care utilization were derived from a sys-
tematic literature review and ofﬁcial statistics. Population data
and prices were taken from ofﬁcial statistics and price com-
pendiums. A payers’ (sickness funds) perspective was taken.
Costs include out- and inpatient care as well as work loss by
parents (considering their labour force participation). The latter
is paid by sickness funds in Germany (i.e. “childcare beneﬁts”).
Price level is that of 2002. RESULTS: Community-acquired RV-
AGE requiring outpatient care occurs each year in nearly
120.000 children aged 0–48 months. 6.1% of those cases require
hospitalisation resulting in about 7.350 inpatient cases and
38.250 inpatient days. Nosocomial infections result in 6.900
additional RV-AGE with a prolonged hospital stay amounting to
10.350 additional inpatient days. Outpatient costs amount to
8.5€m p.a. and account for 27.4% of overall costs. Inpatient care
costs about 15.9€m (51.2%). Childcare beneﬁts amount to
6.6€m (21.4%). Overall costs to payers are 31€m p.a. CON-
CLUSIONS: Rotavirus causes severe acute gastroenteritis among
young children. The overall burden of rotavirus gastroenteritis
is considerable and even underestimated as not all children are
presented to physicians and stool samples are not analysed on a
regular basis. Furthermore, rotavirus causes considerable costs
to health care payers, especially due to hospitalizations and noso-
comial infections.
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